Carrington Names Maria Eaton Vice President, Support Services
Ms. Eaton joined Carrington in 1997 as executive assistant and specialassistant to the CEO. She has since assumed numerous operationalresponsibilities, the most recent of which was director, Support Services.
Carlton Turner, CEO of Carrington said, "Ms. Eaton's promotion to vicepresident is well deserved. She has demonstrated extraordinary ability inmanaging complex operations. She also understands manufacturing andregulatory details required to meet FDA and ISO requirements for each of theproduct groups manufactured by Carrington. Integrating these diverse needsinto a system for efficiency in purchasing, planning, and production hasgreatly reduced our inventory."
Prior to joining Carrington, Ms. Eaton attended the University of NorthTexas and was previously employed in the healthcare industry.
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based,biopharmaceutical and consumer products company currently utilizingnaturally-occurring complex carbohydrates to manufacture and market productsfor mucositis, radiation dermatitis, wound and oral care, as well as tomanufacture and market the nutraceutical raw material Manapol(R) and cosmeticraw material Hydrapol(TM). Carrington also manufactures and markets consumerproducts and manufactures quality products for other companies. Manufacturingoperations comply with cGMP standards. Carrington's DelSite Biotechnologiessubsidiary is developing its proprietary GelSite(R) technology designed toprovide controlled release of peptide and protein-based drugs. Carrington'stechnology is protected by more than 130 patents in 26 countries. Selectproducts carry the CE mark, recognized by more than 20 countries around theworld. For more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risksincluding, but not limited to: subsequent changes in plans by the Company'smanagement; delays or problems in formulation, manufacturing, distribution,production and/or launch of new finished products; changes in the regulatoryprocess; changes in market trends; and a number of other factors and risksdescribed from time to time in the Company's filings with the Securities &Exchange Commission.
SOURCE Carrington Laboratories, Inc.
You May Also Like